Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) finished Friday with an addition of $1.12 to close at $36.95, an upside of 3.13 percent. An average of 521,980 shares of common stock have been traded in the last five days. There was a gain of $0.79 in the past week. The last 20 days have seen an average of 761,375 shares traded, while the 50-day average volume stands at 758,988.
AMLX stock has decreased by -3.70% in the last month. The company shares reached their 1-month lowest point of $32.77 on 12/19/22. Shares of the company touched a low of $6.51 and a high of $39.78 in 52 weeks. In spite of this, the price is down -7.10% from the 52-week high.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
AMLX stock investors should be aware that Amylyx Pharmaceuticals Inc. (AMLX) stock had its last reported insider trading activity 113 days ago on Sep 09. In this transaction, the insider spent $21,159,753. 10% Owner, VIKING GLOBAL INVESTORS LP, disposed of 700,000 shares at a price of $29.37 on Sep 08. The insider now owns more than $20,559,887 worth of shares. Prior to that, 10% Owner ALS Invest 1 B.V. went on to Sale 60,609 shares at $20.70 each on Jul 06. An amount of $1,254,642 was transacted.
Amylyx Pharmaceuticals Inc. (AMLX) has a trailing price-to-sales (P/S) ratio at 8297.74, the price-to-book (PB) ratio at 15.02.
The quick ratio of Amylyx Pharmaceuticals Inc. for the three months ended September 29 was 5.30, and the current ratio was 5.30, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending September 29. Its gross profit as reported stood at $82.97 million compared to revenue of $0.28 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Amylyx Pharmaceuticals Inc.’s return on assets was -93.60%.
For the three-month period that ended September 29, Amylyx Pharmaceuticals Inc. had $54.86 million in cash. The company posted a net income of -$53.76 million in the quarter, while revenues were grew 100.0%. The analyst consensus anticipated Amylyx Pharmaceuticals Inc.’s latest quarter earnings to come in at -$0.97 per share, but it turned out to be -$0.92, a 5.20% surprise. For the quarter, EBITDA amounted to -$54.6 million. Shareholders own equity worth $66.26 million.
From a technical analysis perspective, let’s take a brief look at Amylyx Pharmaceuticals Inc. (AMLX) price momentum. RSI 9-day as of the close on 30 December was 57.25%, suggesting the stock is Neutral, with historical volatility in this time frame at 52.47%.
As of today, AMLX’s price is $35.57 +2.18% or $0.79 from its 5-day moving average. AMLX is currently trading -5.88% lower than its 20-day SMA and +44.90% higher than its 100-day SMA. However, the stock’s current price level is +3.47% above the SMA50 and +58.99% above the SMA200.
The stochastic %K and %D were 56.79% and 46.59%, respectively, and the average true range (ATR) was 1.96. With the 14-day stochastic at 75.68% and the average true range at 1.99, the RSI (14) stands at 54.38%. The stock has reached 0.66 on the 9-day MACD Oscillator while the 14-day reading was at 0.25.
Citigroup launched coverage on Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX) in its analyst report released on May 25, 2022. The firm assigned the stock a Buy rating. The consensus rating for Amylyx Pharmaceuticals Inc. (AMLX) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell AMLX, while 1 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 4 others rate it as a “buy”.
What is AMLX’s price target for the next 12 months?
Analysts predict a range of price targets between $44.00 and $51.00, with a median target of $50.00. Taking a look at these predictions, the average price target given by analysts for Amylyx Pharmaceuticals Inc. (AMLX) stock is $48.75.